| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts
|
|
|
2004
|
|
4 |
p. 1-28
28 p.
|
artikel
|
| 2 |
ADMA and oxidative stress
|
Sydow, Karsten
|
|
2003
|
|
4 |
p. 41-51
11 p.
|
artikel
|
| 3 |
ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease
|
Böger, Rainer H.
|
|
2003
|
|
4 |
p. 23-28
6 p.
|
artikel
|
| 4 |
A new reality: achieving cholesterol-lowering goals in clinical practice
|
Gaw, Allan
|
|
2002
|
|
4 |
p. 5-11
7 p.
|
artikel
|
| 5 |
A scientific rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis
|
Morishita, Ryuichi
|
|
2005
|
|
4 |
p. 41-46
6 p.
|
artikel
|
| 6 |
Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events
|
Valkonen, Veli-Pekka
|
|
2003
|
|
4 |
p. 19-22
4 p.
|
artikel
|
| 7 |
Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase
|
Böger, Rainer H.
|
|
2003
|
|
4 |
p. 1-3
3 p.
|
artikel
|
| 8 |
ATP-binding cassette A1 protein and HDL homeostasis
|
Owen, James S
|
|
2002
|
|
4 |
p. 13-22
10 p.
|
artikel
|
| 9 |
Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study
|
Matsumoto, Masayasu
|
|
2005
|
|
4 |
p. 33-40
8 p.
|
artikel
|
| 10 |
Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding
|
Goto, Shinya
|
|
2005
|
|
4 |
p. 3-11
9 p.
|
artikel
|
| 11 |
Corrigendum to “Trans-fatty acids and sudden cardiac death” [Atheroscler. Suppl. 7 (2006) 13–15]
|
Lemaitre, Rozenn N.
|
|
2006
|
|
4 |
p. 33-
1 p.
|
artikel
|
| 12 |
Editorial Board
|
|
|
2005
|
|
4 |
p. iii-
1 p.
|
artikel
|
| 13 |
Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination
|
Comerota, Anthony J.
|
|
2005
|
|
4 |
p. 13-19
7 p.
|
artikel
|
| 14 |
Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II
|
De Backer, Guy
|
|
2002
|
|
4 |
p. 13-17
5 p.
|
artikel
|
| 15 |
HDL in risk prediction and its direct and indirect involvement in atherogenesis
|
Durrington, Paul
|
|
2002
|
|
4 |
p. 3-12
10 p.
|
artikel
|
| 16 |
HDL therapy for the acute treatment of atherosclerosis
|
Newton, Roger S
|
|
2002
|
|
4 |
p. 31-38
8 p.
|
artikel
|
| 17 |
Healthy food and healthy choices: A new European profile approach
|
|
|
2009
|
|
4 |
p. 1-11
11 p.
|
artikel
|
| 18 |
High risk/high priority: familial hypercholesterolemia — a paradigm for molecular medicine
|
Schuster, Herbert
|
|
2002
|
|
4 |
p. 27-32
6 p.
|
artikel
|
| 19 |
Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors
|
Barter, P.J
|
|
2002
|
|
4 |
p. 39-47
9 p.
|
artikel
|
| 20 |
Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA
|
Lentz, Steven R.
|
|
2003
|
|
4 |
p. 61-65
5 p.
|
artikel
|
| 21 |
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
|
Tselepis, Alexandros D
|
|
2002
|
|
4 |
p. 57-68
12 p.
|
artikel
|
| 22 |
Introduction
|
Durrington, Paul
|
|
2002
|
|
4 |
p. 1-
1 p.
|
artikel
|
| 23 |
Introduction
|
Chait, Alan
|
|
2006
|
|
4 |
p. 1-4
4 p.
|
artikel
|
| 24 |
Introduction
|
Hiatt, W.R.
|
|
2005
|
|
4 |
p. 1-
1 p.
|
artikel
|
| 25 |
Is insulin resistance atherogenic? A review of the evidence
|
Ferrannini, Ele
|
|
2006
|
|
4 |
p. 5-10
6 p.
|
artikel
|
| 26 |
Is insulin resistance atherogenic? Possible mechanisms
|
DeFronzo, Ralph A.
|
|
2006
|
|
4 |
p. 11-15
5 p.
|
artikel
|
| 27 |
Lectures in the 3rd Baltic Atherosclerosis Congress Supplement
|
|
|
2004
|
|
4 |
p. 29-41
13 p.
|
artikel
|
| 28 |
Lipid-lowering — translating evidence into benefits
|
Shepherd, James
|
|
2002
|
|
4 |
p. 1-3
3 p.
|
artikel
|
| 29 |
Managing diabetic dyslipidaemia—beyond LDL-C:HDL-C and triglycerides
|
Barter, Philip
|
|
2006
|
|
4 |
p. 17-21
5 p.
|
artikel
|
| 30 |
NO and angiogenesis
|
Cooke, John P.
|
|
2003
|
|
4 |
p. 53-60
8 p.
|
artikel
|
| 31 |
Old and new cardiovascular risk factors: from unresolved issues to new opportunities
|
Maas, Renke
|
|
2003
|
|
4 |
p. 5-17
13 p.
|
artikel
|
| 32 |
Optimizing the pharmacology of statins: characteristics of rosuvastatin
|
Chapman, M.John
|
|
2002
|
|
4 |
p. 33-37
5 p.
|
artikel
|
| 33 |
Paraoxonase and coronary heart disease
|
Mackness, Michael I
|
|
2002
|
|
4 |
p. 49-55
7 p.
|
artikel
|
| 34 |
Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study
|
Mügge, Andreas
|
|
2003
|
|
4 |
p. 29-32
4 p.
|
artikel
|
| 35 |
Preface
|
|
|
2004
|
|
4 |
p. x-
1 p.
|
artikel
|
| 36 |
Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL
|
Angelin, Bo
|
|
2002
|
|
4 |
p. 23-30
8 p.
|
artikel
|
| 37 |
Role of adjunct pharmacologic therapy in the era of drug-eluting stents
|
Douglas Jr., John S.
|
|
2005
|
|
4 |
p. 47-52
6 p.
|
artikel
|
| 38 |
The apolipoprotein story
|
Sacks, Frank M.
|
|
2006
|
|
4 |
p. 23-27
5 p.
|
artikel
|
| 39 |
The DDAH/ADMA/NOS pathway
|
Tran, Cam T.L
|
|
2003
|
|
4 |
p. 33-40
8 p.
|
artikel
|
| 40 |
The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment
|
Stein, Evan
|
|
2002
|
|
4 |
p. 19-25
7 p.
|
artikel
|
| 41 |
The US experience with cilostazol in treating intermittent claudication
|
Hiatt, William R.
|
|
2005
|
|
4 |
p. 21-31
11 p.
|
artikel
|
| 42 |
Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatment goals
|
Hobbs, F.D. Richard
|
|
2006
|
|
4 |
p. 29-32
4 p.
|
artikel
|
Tijdschrift beschrijving